The RADIANT trial enrolled patients with fully resected stage IB to IIIA NSCLC and confirmed tumor EGFR expression by immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH). This evidence concerns the gene EGFR and neoplasm.